search
Back to results

Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
CKD-330 16/5mg - A
Candesartan 16mg and Amlodipine 5mg
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

19 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy male volunteer in the age between 19 and 45 years old.
  2. Body weight ≥ 55 kg and Body weight in the range of calculated IBW ±20%.
  3. Subjects without a hereditary problems and chronic disease.
  4. Subjects whose clinical laboratory test values are inside the accepted normal range.
  5. Understand the requirements of the study and voluntarily consent to participate in the study.

Exclusion Criteria:

  1. Previous history or present of clinically significant hepatobiliary, nephrological, neurologic, respiratory, hemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system.
  2. History of gastrointestinal disease or gastrointestinal surgery to affect drug absorption.
  3. History of clinically significant allergies of amlodipine or candesartan or CCB or ARB or aspirin or antibiotic.
  4. Subjects with galactose intolerance.
  5. SBP ≥ 140 mmHg or< 90 mmHg, DBP ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 BPM.
  6. AST or ALT > 2*ULN, total bilirubin > 2*ULN
  7. Serum Creatinine > ULN
  8. Previous history or present of drug abuse.
  9. Subjects treated metabolizing enzyme inducers or inhibitors such as barbitals within 1 month prior to the first dosing.
  10. Subjects treated ethical drug or herbal medicine within 2 weeks, OTC or vitamin within 1 week prior to the first dosing.
  11. Subjects treated IP within 2 months prior to the first dosing.
  12. Subjects with whole blood donation within 2 months or component blood donation within 1 month or blood transfusion within 1 month prior to the first dosing.
  13. Alcohol > 21 units/week or cannot stop drinking.
  14. Cigarette > 10 cigarettes/day.
  15. Subjects with the plan dental treatment(extraction, orthodontic, nerve treatment) or any surgery(plastic surgery, eye surgery - LASIK, LASEK).
  16. Not eligible to participate for the study at the discretion of investigator.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Candesartan and Amlodipine

    CKD-330

    Arm Description

    Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days

    CKD-330 16/5mg - A, PO, 1days or 22days

    Outcomes

    Primary Outcome Measures

    AUCt
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Cmax
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr

    Secondary Outcome Measures

    AUCinf
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    tmax
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    t1/2β
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    CL/F
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr

    Full Information

    First Posted
    June 12, 2016
    Last Updated
    June 12, 2016
    Sponsor
    Chong Kun Dang Pharmaceutical
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02801526
    Brief Title
    Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A
    Official Title
    A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers (A)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2015 (undefined)
    Primary Completion Date
    May 2015 (Actual)
    Study Completion Date
    August 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Chong Kun Dang Pharmaceutical

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan 16 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    32 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Candesartan and Amlodipine
    Arm Type
    Experimental
    Arm Description
    Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
    Arm Title
    CKD-330
    Arm Type
    Experimental
    Arm Description
    CKD-330 16/5mg - A, PO, 1days or 22days
    Intervention Type
    Drug
    Intervention Name(s)
    CKD-330 16/5mg - A
    Intervention Type
    Drug
    Intervention Name(s)
    Candesartan 16mg and Amlodipine 5mg
    Primary Outcome Measure Information:
    Title
    AUCt
    Description
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Time Frame
    0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Title
    Cmax
    Description
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Time Frame
    0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Secondary Outcome Measure Information:
    Title
    AUCinf
    Description
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Time Frame
    0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Title
    tmax
    Description
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Time Frame
    0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Title
    t1/2β
    Description
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Time Frame
    0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Title
    CL/F
    Description
    A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
    Time Frame
    0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    19 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Healthy male volunteer in the age between 19 and 45 years old. Body weight ≥ 55 kg and Body weight in the range of calculated IBW ±20%. Subjects without a hereditary problems and chronic disease. Subjects whose clinical laboratory test values are inside the accepted normal range. Understand the requirements of the study and voluntarily consent to participate in the study. Exclusion Criteria: Previous history or present of clinically significant hepatobiliary, nephrological, neurologic, respiratory, hemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system. History of gastrointestinal disease or gastrointestinal surgery to affect drug absorption. History of clinically significant allergies of amlodipine or candesartan or CCB or ARB or aspirin or antibiotic. Subjects with galactose intolerance. SBP ≥ 140 mmHg or< 90 mmHg, DBP ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 BPM. AST or ALT > 2*ULN, total bilirubin > 2*ULN Serum Creatinine > ULN Previous history or present of drug abuse. Subjects treated metabolizing enzyme inducers or inhibitors such as barbitals within 1 month prior to the first dosing. Subjects treated ethical drug or herbal medicine within 2 weeks, OTC or vitamin within 1 week prior to the first dosing. Subjects treated IP within 2 months prior to the first dosing. Subjects with whole blood donation within 2 months or component blood donation within 1 month or blood transfusion within 1 month prior to the first dosing. Alcohol > 21 units/week or cannot stop drinking. Cigarette > 10 cigarettes/day. Subjects with the plan dental treatment(extraction, orthodontic, nerve treatment) or any surgery(plastic surgery, eye surgery - LASIK, LASEK). Not eligible to participate for the study at the discretion of investigator.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jang Hee Hong
    Organizational Affiliation
    Chungnam National University Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A

    We'll reach out to this number within 24 hrs